Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021

Mar 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-03-04

Reporting Person: Stark David Matthew (Exec. VP Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Ordinary Shares	M	13930	—	Acquired	16904.39	Direct
2021-03-04	Ordinary Shares	S	13930	$10.5661	Disposed	2974.39	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Restricted Share Units	$	M	13930	Disposed		Ordinary Shares (13930)	Direct
2021-03-05	Restricted Share Units	$	A	80798	Acquired		Ordinary Shares (80798)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023.

F6: Restricted share units were granted on March 5, 2021, with 20,199 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024, and 20,201 vesting on March 5, 2025.